Joseph W Chow

List of Publications by Year
in descending order

50 papers	4,345 citations	186209 28 h-index	206029 48 g-index
50 all docs	50 docs citations	50 times ranked	3558 citing authors

#	Article	IF	Citations
1	Enterobacter Bacteremia: Clinical Features and Emergence of Antibiotic Resistance during Therapy. Annals of Internal Medicine, 1991, 115, 585-590.	2.0	797
2	Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infectious Diseases, The, 2018, 18, 285-295.	4.6	300
3	Determinants of Vancomycin Resistance and Mortality Rates in Enterococcal Bacteremia: A Prospective Multicenter Study. Annals of Internal Medicine, 2001, 135, 484.	2.0	273
4	Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. International Journal of Antimicrobial Agents, 1999, 11, 7-12.	1.1	261
5	Aminoglycoside Resistance in Enterococci. Clinical Infectious Diseases, 2000, 31, 586-589.	2.9	256
6	Simple and Reliable Multiplex PCR Assay for Surveillance Isolates of Vancomycin-Resistant Enterococci. Journal of Clinical Microbiology, 2000, 38, 3092-3095.	1.8	253
7	Multiplex PCR for Detection of Aminoglycoside Resistance Genes in Enterococci. Antimicrobial Agents and Chemotherapy, 2003, 47, 1423-1426.	1.4	204
8	In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). Journal of Antimicrobial Chemotherapy, 2005, 55, 965-973.	1.3	155
9	In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring) Tj ETQq1 1 0.784314 rgBT /Ove	1.3	134
10	A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia. Pediatric Infectious Disease Journal, 2010, 29, 415-420.	1.1	135
11	Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age. Antimicrobial Agents and Chemotherapy, 2009, 53, 869-875.	1.4	131
12	A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients. Pediatrics, 2009, 123, 877-884.	1.0	123
13	Association between the Presence of Enterococcal Virulence Factors Gelatinase, Hemolysin, and Enterococcal Surface Protein and Mortality among Patients with Bacteremia Due toEnterococcus faecalis. Clinical Infectious Diseases, 2002, 35, 570-575.	2.9	108
14	A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. International Journal of Antimicrobial Agents, 2017, 49, 579-588.	1.1	100
15	Detection of the High-Level Aminoglycoside Resistance Gene aph(2")-Ib in Enterococcus faecium. Antimicrobial Agents and Chemotherapy, 2000, 44, 2876-2879.	1.4	92
16	Emergence of Increased Resistance to Quinupristin/ Dalfopristin During Therapy for Enterococcus faecium Bacteremia. Clinical Infectious Diseases, 1997, 24, 90-91.	2.9	91
17	A New High-Level Gentamicin Resistance Gene, aph(2")-Id , in Enterococcus spp. Antimicrobial Agents and Chemotherapy, 1998, 42, 1229-1232.	1.4	90
18	Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes. Journal of Antimicrobial Chemotherapy, 1991, 28, 499-504.	1.3	85

#	Article	IF	Citations
19	Aminoglycoside Resistance Genes aph(2")-Ib and aac(6â€²)-Im Detected Together in Strains of both Escherichia coli and Enterococcus faecium. Antimicrobial Agents and Chemotherapy, 2001, 45, 2691-2694.	1.4	58
20	Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. Journal of Antimicrobial Chemotherapy, 2018, 73, 2519-2523.	1.3	56
21	Molecular Analysis of Glycopeptide-Resistant Enterococcus faecium Isolates Collected from Michigan Hospitals over a 6-Year Period. Journal of Clinical Microbiology, 1998, 36, 3303-3308.	1.8	55
22	In Vitro Susceptibilities of Aerobic and Facultatively Anaerobic Gram-Negative Bacilli Isolated from Patients with Intra-Abdominal Infections Worldwide: 2005 Results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surgical Infections, 2009, 10, 99-104.	0.7	49
23	In Vitro Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli Isolated from Patients with Intra- Abdominal Infections Worldwide: The 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surgical Infections, 2005, 6, 439-448.	0.7	48
24	Acquisition of Resistant Bowel Flora during a Double-Blind Randomized Clinical Trial of Ertapenem versus Piperacillin-Tazobactam Therapy for Intraabdominal Infections. Antimicrobial Agents and Chemotherapy, 2005, 49, 3217-3221.	1.4	46
25	Acquired Antibiotic Resistances in Enterococci. , 0, , 355-383.		40
26	SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS. Pediatric Infectious Disease Journal, 2009, 28, 1132-1135.	1.1	36
27	In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci. Diagnostic Microbiology and Infectious Disease, 1993, 17, 151-155.	0.8	34
28	Heteroresistance to Vancomycin in Enterococcus faecium. Journal of Clinical Microbiology, 2001, 39, 3379-3381.	1.8	33
29	Source of Phosphate in the Enzymic Reaction as a Point of Distinction among Aminoglycoside 2â€³-Phosphotransferases. Journal of Biological Chemistry, 2009, 284, 6690-6696.	1.6	33
30	In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureusâ˜†. Diagnostic Microbiology and Infectious Disease, 2000, 36, 37-41.	0.8	29
31	In Vitro Susceptibilities ofEscherichia coliIsolated from Patients with Intra-Abdominal Infections Worldwide in 2002â€“2004: Results from SMART (Study for Monitoring Antimicrobial Resistance) Tj ETQq1 1 0.784314 rgBT /Overlock		
32	In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asiaâ€“Pacific region: 2004 results from SMART (Study for Monitoring) Tj ETQq0 0 1 rgBT /Overlock 10		
33	Kinetic Mechanism of Enterococcal Aminoglycoside Phosphotransferase 2â€˜â€‰â€˜-Ib. Biochemistry, 2007, 46, 5570-5578.	1.2	22
34	In vitro susceptibility and molecular analysis of gentamicin-resistant enterococci. Diagnostic Microbiology and Infectious Disease, 1998, 32, 141-146.	0.8	17
35	Antibiotic Studies in Pneumonia. Chest, 1989, 96, 453-456.	0.4	15
36	Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. Infectious Diseases and Therapy, 2021, 10, 2399-2414.	1.8	15

#	Article	IF	Citations
37	Aminoglycoside 2â€³-Phosphotransferase Type IIIa from Enterococcus. Journal of Biological Chemistry, 2008, 283, 7638-7647.	1.6	13
38	Efficacy of Ampicillin plus Arbekacin in Experimental Rabbit Endocarditis Caused by an Enterococcus faecalis Strain with High-Level Gentamicin Resistance. Antimicrobial Agents and Chemotherapy, 2000, 44, 2545-2546.	1.4	12
39	In-vitro synergistic activity of the combination of ampicillin and arbekacin against vancomycin-and high-level gentamicin-resistant Enterococcus faecium with the aph(2â€)-Id gene. Diagnostic Microbiology and Infectious Disease, 2000, 37, 297-299.	0.8	11
40	Mutant APH(2â€³)-IIa Enzymes with Increased Activity against Amikacin and Isepamicin. Antimicrobial Agents and Chemotherapy, 2010, 54, 1590-1595.	1.4	11
41	Safety Profile of Ceftazidimeâ€“Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme. Drug Safety, 2020, 43, 751-766.	1.4	11
42	Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy. Diagnostic Microbiology and Infectious Disease, 2007, 58, 491-494.	0.8	10
43	In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
44	Synergistic interaction of antibiotics with nasal penetration to methicillin-sensitive and methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 1991, 27, 558-560.	1.3	6
45	Mutations in the aph(2")-Ic Gene Are Responsible for Increased Levels of Aminoglycoside Resistance. Antimicrobial Agents and Chemotherapy, 2002, 46, 3253-3256.	1.4	5
46	Failure of oral ciprofloxacin in suppressing Staphylococcus aureus carriage in haemodialysis patients. Journal of Antimicrobial Chemotherapy, 1992, 29, 88-89.	1.3	4
47	Purification, crystallization and preliminary X-ray analysis ofEnterococcus faeciumaminoglycoside-2â€²â€²-phosphotransferase-Ib [APH(2â€²â€²)-Ib]. Acta Crystallographica Section F: Structural Biology Communications, 2005, 61, 410-413.	0.7	3
48	Quantitative comparison in vitro of mutational antibiotic resistance of Enterobacter spp. using a spiral plater. Journal of Antimicrobial Chemotherapy, 1996, 37, 233-242.	1.3	2
49	Caspofungin exposureâ€response relationships in adult patients with mucosal or invasive candidiasis. Clinical Pharmacology in Drug Development, 2014, 3, 43-50.	0.8	1
50	Caspofungin Versus Liposomal Amphotericin B. Pediatric Infectious Disease Journal, 2010, 29, 986-987.	1.1	0